When I originally searched SS31 in the search bar nothing popped up, than I went into the posts on the side and found it & did some reading!
I see HK Peptide has it for a decent price, just haven’t seen many reviews on here from that vendor…
Nexa usually has reasonable prices when you compare 10mg to 30mg kits (theirs is 30mg)
my exact thought, how do you quantify this?
Hello
ojrd.biomedcentral.com
No, I was referring to studies directly on humans. Not isolated mitochondria, not animal tests and not in vitro. We spent a few weeks in 2023 reviewing SS-31 and were unable to locate one test that confirmed success in humans. Granted we only searched, Eastern Europe and Southeast Asia. So there may be some out there that we didn't find. Don't get me wrong, I said the mechanism is legit, as I have read through most of the studies you shared. I don't dispute the mechanism, I just have not been able to verify actual human response. I will read thhrough that middle one you shared there as it is a new one to me. It looks promising.If you are referring to the MMPOWER-3 trial:
Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial - Orphanet Journal of Rare Diseases
Background As previously published, the MMPOWER-3 clinical trial did not demonstrate a significant benefit of elamipretide treatment in a genotypically diverse population of adults with primary mitochondrial myopathy (PMM). However, the prespecified subgroup of subjects with disease-causing...
"Post hoc analyses indicated that elamipretide had a beneficial effect in PMM patients with mtDNA replisome disorders, underscoring the importance of considering specific genetic subtypes in PMM clinical trials. These data serve as the foundation for a follow-up Phase 3 clinical trial (NuPOWER) which has been designed as described in this paper to determine the efficacy of elamipretide in patients with mtDNA maintenance-related disorders."
Human studies of SS-31 with good results:
"Treatment of explanted human hearts with elamipretide [SS-31] improves human cardiac mitochondrial function."
"During PTRA, patients were assigned randomly to either elamipretide (0.05 mg/kg per hour, n=6) or identically prepared placebo (n=8) infusion, which started 30 minutes before PTRA."
"Adjunctive elamipretide during PTRA was associated with attenuated postprocedural hypoxia, increased RBF, and improved kidney function in this pilot trial. These data support a role for targeted mitochondrial protection to minimize procedure-associated ischemic injury and to improve outcomes of revascularization for human atherosclerotic renal artery stenosis."
Similarly, a dog study with good results for heart failure:
"Long-term therapy with elamipretide improves LV systolic function, normalizes plasma biomarkers, and reverses mitochondrial abnormalities in LV myocardium of dogs with advanced HF. The results support the development of elamipretide for the treatment of HF."
There are several. I do not remember it but a google scholar search or if you have access to a scientific library like we do, should yield them. It was study on people with mitochandrial myeopathy, speciifically i believe it was inherited. The only success at all was slight and it was only iin people who had a specific mutation of a specific cardiolipin. For all others, it failed. That does not mean that the mechanism is not intact but for its intended purpose, it failed. There is another one that shows it was beneficial for eyes, but since ss-31 targets cardiolipins specifically and in the human study looking for repair to cardiolipins, it only worked in people with a specific mutation.
